Clinical, radiological, and pathological features of 33 adult unilateral thalamic gliomas

Peng Zhang, Xingchao Wang, Nan Ji, Jian Xie, Jinsong Han, Xiaohui Ren, Guidong Song, Ruofei Wu, Liwei Zhang, and Zhixian Gao

Abstract

Background: Unilateral adult thalamic gliomas are rarely reported. In this study, the authors aimed to analyze the clinical, radiological, and pathological features of adult primary unilateral thalamus gliomas (UTGs).

Methods: Clinical data of 33 UTGs in adults who underwent surgical treatment between 2005 and 2014 at the Beijing Tiantan Hospital were collected and retrospectively studied. Follow-up evaluation was performed.

Results: This study included 21 males and 12 females with a mean age of 43.1 years. The most common symptoms were headache (75.8 %, 25/33 patients) and motor deficits (42.4 %, 14/33 patients). Radiological results showed that enhancement was common (90.9 %, 30/33 patients) and included cystic appearances in 9 cases (27.3 %). All patients underwent maximal safe tumor resection. Gross total resection (GTR) was achieved in 19 cases, subtotal resection (≥80 %) in 9 cases, and partial resection (<80 %) in 5 cases. Molecular pathology results were available in 15 cases. After surgery, 25 patients received postoperative adjuvant therapy based on the remaining pathology. The median follow-up period of all 33 patients with UTGs was 17 months (1 week~49 months). Twenty-four patients experienced tumor recurrence. The 1-year and 2-year progression-free survival (PFS) rates were 49.0 and 10.2 %, respectively. The 1-year and 2-year overall survival (OS) rates were 68.1 and 25.9 %, respectively. Survival analyses revealed that several predictive factors were correlated with better prognosis, among which, GTR and tumor with cystic appearances were significantly associated with a longer survival.

Conclusions: Adult UTGs displayed a wide spectrum of clinical features. GTR can be achieved in adult UTGs with acceptable complications and conferred a better prognosis. Tumor with cystic appearance may indicate better prognosis. More patients and longer follow-up periods are needed to further elucidate the biological features of adult UTGs.

Keywords: Unilateral thalamic glioma, Prognosis, Gross total resection
would benefit adult patients, and the prognosis of this age group remains unknown. In this series, we retrospectively reviewed patients with primary unilateral thalamic glioma who underwent surgical operation at our hospital over a period of 9 years. The aims were to clarify the clinical, radiological, and pathological features and the behavior and response to treatment and to identify the prognostic factors of this diverse group of tumors.

**Methods**

**Patient characteristics and inclusion/exclusion criteria**

Consecutive patients’ notes and imaging studies were reviewed; all included patients underwent operation between 2005 and 2014 at the Beijing Tiantan Hospital. Informed consent was provided by all patients or their family members under an Institutional Review Board-approved protocol at the Beijing Tiantan Hospital of the Capital Medical University.

Our current study used the following inclusion criteria: (1) histological diagnosis of gliomas and (2) patient age older than 18 years at the time of diagnosis while gliomas originating from adjacent structures but secondarily involving thalamus and primary bilateral thalamic gliomas were excluded, but the contralateral growth of a unilateral tumor was included in the study.

Clinical data, including age at presentation, sex, duration and type of symptoms, preoperative Karnofsky Performance Status (KPS), side, cystic appearance, maximal tumor diameter, treatment received, and status at the end of the follow-up period, were recorded. All patients underwent neuraxis magnetic resonance imaging (MRI) prior to treatment and during the follow-up period. All neuroimages and histological specimens were interpreted by two senior neuroradiologist and two neuropathologists, respectively. The T2/FLAIR images were used for defining the tumor diameter. And the enhancing lesion present was also considered together with the T2/FLAIR for defining tumor diameter.

**Treatment protocols**

All included unilateral thalamus glioma (UTG) patients underwent tumor resection surgery aimed at achieving maximal safe tumor resection. The extent of tumor resection was determined on the basis of early postsurgical imaging and/or the neurosurgical report. Gross total tumor resection was defined as macroscopic total removal of the tumor mass, subtotal tumor resection was defined as a removal of ≥80 % of the tumor mass, and partial tumor resection was defined as <80 % resection. Various surgical approaches (the precentral interhemispheric transcallosal interfornical approach, frontal transcortical approach, and parieto-occipital transventricular approach) were used. Postoperative adjuvant therapy was administrated based on the pathology diagnosis as well as the extent of tumor resection. All patients received prophylactic antiepileptic treatments postoperatively for 1 week.

**Statistical analysis**

Statistical analysis was performed retrospectively using the SPSS statistical package 16.0 (SPSS Inc). Overall survival (OS) and progression-free survival (PFS) were determined using Kaplan-Meier analysis and a log-rank test. Events were defined as tumor relapse or progression, occurrence of a secondary malignancy, or death due to any cause. All of the clinical data of the one perioperative death and the other two lost cases (lost to follow-up after discharging from the hospital) were excluded prior to prognostic relevance analysis. All UTGs were defined according to the following parameters: sex, age at diagnosis, symptom lateral, cystic appearance of tumors, maximum tumor diameter, preoperative KPS status, grading of tumors, preoperative ventriculo-peritoneal (V-P) shunt, postoperative V-P shunt, and extent of tumor resection. The cutoff points were set as the median number for both categorical variables and continuous variables under consideration of the clinical practice (Table 5).

The prognostic relevance regarding PFS or OS of all remaining thalamic gliomas was compared to establish subgroups of the parameters defined above. The survival analysis was completed for the same subgroups using a Cox regression analysis. To compare the correlations between different subgroups, we performed the two-sided chi-square test to determine the significances for each parameter. The significance level was set at \( P < 0.05 \).

**Results**

**Clinical, radiological features of patients with UTGs**

Using the selection criteria, we identified 33 patients with UTGs. The clinical and histological characteristics of the 33 cases of UTGs in the present study are summarized in Table 1. Magnetic resonance images were available in all 33 UTGs (Table 2). The symptom duration from onset to hospital admission ranged from 1 week to 12 months; the median duration was 2 months. Among the 33 patients, 25 patients had headaches; 14 had motor deficits; 10 had hyperesthesia; 8 had blurred vision; 7 had hypomnesia; 7 had dysphasia; and 1 had facial palsy. The median preoperative KPS was 60 (ranging from 40 to 80). The postoperative KPS was not collected.

All patients received maximal safe tumor resection under the guidance of intraoperative ultrasound monitoring. No patient received preoperative chemotherapy and/or radiotherapy. Most of the patients received postoperative adjuvant therapy (Table 1). Three patients received clinical follow-ups without further treatment. One of these patients was a middle-aged man who refused to receive and adjuvant therapy and died 3 months after gross total resection of the tumor due to glioblastoma, the second
patient was a young man who remains alive with no progression of disease after receiving a gross total resection of his thalamic glioma with the diagnosis of astrocytoma, and the third patient was a middle-aged woman who refused to receive any adjuvant therapy and died 3 months after partial resection of the tumor due to glioblastoma.

Perioperative management of cerebral spinal fluid problems
Ventriculomagely was identified in 27 of the 33 cases (81.8 %). Seven of the 27 cases (25.9 %) required an emergent V-P shunt. All 7 V-P shunts were performed in the ventricle contra-lateral to the lesion at 5 to 45 days (median 12 days) prior to tumor resection. The other 20

Table 1 Clinical, radiological, and pathological features of 33 adult UTGs

| No. | Age (years) | Sex | Tumor location | Side | Diameter (cm) | Resection | Pathology | Postop therapy | Follow-up time | Status at the last follow-up |
|-----|-------------|-----|----------------|------|---------------|-----------|-----------|---------------|----------------|-------------------------------|
| 1   | 53          | M   | Th + Mid       | Left | 3.8           | STR       | A         | Radio         | 25.5           | Death with progression       |
| 2   | 20          | F   | Th + Mid       | Right| 4.1           | PR        | GBM       | Radio         | 21             | Death with progression       |
| 3   | 20          | M   | Th + IC        | Right| 4.2           | STR       | AA        | Radio         | 17             | Death with progression       |
| 4   | 33          | M   | Th + Mid       | Right| 4.1           | GTR       | OA        | Radio         | 24             | Death with progression       |
| 5   | 32          | F   | Th             | Right| 3.1           | GTR       | AA        | Radio         | 24             | Death with progression       |
| 6   | 47          | F   | Th + BG        | Left | 3.5           | GTR       | GBM       | Radio         | 30             | Death with progression       |
| 7   | 38          | M   | Th + Mid       | Right| 3.4           | STR       | AA        | Radio         | 14             | Death with progression       |
| 8   | 37          | M   | Th             | Left | 3.9           | GTR       | A         | Radio         | 24             | Death with progression       |
| 9   | 56          | M   | Th             | Left | 1.2           | GTR       | A         | Radio         | 46             | Alive without progression    |
| 10  | 42          | M   | Th             | Right| 3.2           | GTR       | GBM       | Radio         | 49             | Alive with progression       |
| 11  | 21          | F   | Th             | Left | 4.5           | STR       | AA        | Radio         | 17             | Death with progression       |
| 12  | 37          | M   | Th + IC        | Left | 3.5           | GTR       | GBM       | Radio         | 14             | Death with progression       |
| 13  | 29          | M   | Th + Mid + IC  | Right| 4.1           | GTR       | A         | Radio         | 35             | Death with progression       |
| 14  | 46          | M   | Th + IC        | Left | 5.3           | GTR       | GBM       | –             | 1              | Death without progression    |
| 15  | 33          | M   | Th + IC        | Right| 6.2           | PR        | GBM       | –             | –              | Lost to follow-up            |
| 16  | 29          | M   | Th + IC + PiR  | Right| 4.5           | GTR       | OA^b       | Radio + chemo | 25            | Death with progression       |
| 17  | 49          | F   | Th             | Right| 3.5           | GTR       | AA        | Radio         | 17             | Death with progression       |
| 18  | 48          | M   | Th             | Left | 4.2           | GTR       | AO^b       | Radio + chemo | 27            | Death with progression       |
| 19  | 36          | M   | Th + IC + CTh  | Right| 3.2           | PR        | AOA^b      | Radio         | 20             | Death without progression    |
| 20  | 24          | M   | Th + Mid + IC  | Left | 5.4           | GTR       | A^b        | –             | 14             | Alive without progression    |
| 21  | 52          | F   | Th + CTh       | Right| 2.5           | STR       | AO^b       | Radio + chemo | 2              | Death with progression       |
| 22  | 21          | F   | Th + Mid       | Right| 3.8           | STR       | AOA^b      | Radio + chemo | 12            | Alive without progression    |
| 23  | 45          | F   | Th + Mid       | Right| 4.2           | GTR       | GBM^c      | Radio + chemo | 3              | Death without progression    |
| 24  | 30          | M   | Th             | Right| 3.9           | GTR       | GBM^c      | Radio + chemo | 11            | Alive with progression       |
| 25  | 43          | M   | Th             | Right| 4.7           | GTR       | AA^b       | Radio + chemo | 11            | Alive without progression    |
| 26  | 63          | F   | Th + IC        | Left | 4.1           | GTR       | OA^b       | Chemo         | 16             | Alive with progression       |
| 27  | 47          | F   | Th + BG + IC   | Left | 3.4           | PR        | GBM^c      | Radio + chemo | 4              | Alive without progression    |
| 28  | 45          | F   | Th + IC        | Right| 4.8           | PR        | GBM^c      | –             | 3              | Death without progression    |
| 29  | 20          | M   | Th + Mid       | Right| 5.3           | STR       | AA^b       | Radio + chemo | 21            | Death with progression       |
| 30  | 53          | F   | Th + CTh       | Left | 5.1           | GTR       | OA^b       | –             | –              | Lost to follow-up            |
| 31  | 31          | M   | Th + Mid + IC  | Left | 5.2           | STR       | AOA^b      | Radio         | 24             | Death with progression       |
| 32  | 66          | M   | Th + Mid + IC  | Right| 4.5           | GTR       | GSM       | Chemo         | 1 week         | Perioperative death          |
| 33  | 48          | M   | Th + Mid       | Left | 5.2           | STR       | GBM^c      | Radio + chemo | 13            | Death with progression       |

Th thalamus, Mid midbrain, IC internal capsule, BG basal ganglia, PiR pineal region, CTh contralateral thalamus, GTR gross total resection (≥90 % resection), STR subtotal resection (≥80 but <90 %), PR partial resection (<80 %), A astrocytoma, AA anaplastic astrocytoma, AO anaplastic oligodendroglioma, AOA anaplastic oligodendroastrocytoma, GBM glioblastoma, GSM gliosarcoma, OA oligoastrocytoma

aThe follow-up time take the month as the unit

bThe molecular pathologies were available
patients with some degree of ventriculomegaly were not treated, thereby leaving additional room to facilitate tumor resection through a transventricular approach.

After tumor resection, 4 patients with UTG (12.1 %) developed hydrocephalus and received V-P shunts in the ventricle contra-lateral to the lesion at 10, 13, 30, or 45 days after tumor resection, respectively.

Surgical findings and outcomes of patients with UTGs
The surgical findings and outcomes are summarized in Table 3. The choice of the surgical approaches was based on the tumor location as well as the preferences of surgeon. The frontal transcortical approach was taken to remove tumors located in the anterior part of the unilateral thalamus in 6 cases, the precentral interhemispheric transcallosal interforniceal approach was taken to remove tumors located in the middle part of the unilateral thalamus in 5 cases, and the parieto-occipital transventricular approach was taken to remove tumors located in the posterior part of the unilateral thalamus in 22 cases. Of note, when the tumors are located in the posterior part of the left thalamus, the language function area should be cautiously protected. Perioperative death occurred in one case after tumor resection due to postoperative malignant brain edema.

After tumor resection, headaches were significantly relieved or eliminated in 25 cases. Among the 14 patients with preoperative motor deficits, 4 cases demonstrated obvious improvement, 5 cases showed no significant changes, and 5 cases exhibited postoperatively deterioration, including the one death due to postoperative malignant brain edema. In the 10 cases with preoperative hyperesthesia, obvious improvement was observed in 2 cases; the other 8 cases showed no significant changes or deterioration. All 8 patients with blurred vision lost the symptom postoperatively. Among the 7 patients with hypomnesia, obvious improvement was observed in 5 cases and no significant improvement in the remaining 2. Among the 7 patients with dysphasia, obvious improvement was observed in 4 cases, no changes in 2 cases, and deterioration in 1 case. The one patient with facial palsy demonstrated no obvious improvements after operation and finally lost to follow-up.

After the operation, new hemiparesis occurred was observed in 8 cases. Transitory worsening of hemiparesis but significant improvement within 2 weeks was observed in 6

| Table 2 Image features of 33 adult UTGs |
| Characteristics                             | No. (%) of patients |
| Location of tumors                          |                     |
| Confined in the thalamus                    | 9 (27.3)            |
| Extension to the brainstem                  | 12 (36.4) (including 4 extensions to the basal ganglia or internal capsule and 1 extension to the contralateral thalamus) |
| Extension to the contralateral thalamus     | 3 (9.1) (including 1 extension to the brainstem and 1 extension to the internal capsule) |
| Extension to the basal ganglia and/or internal capsule | 14 (42.4) (including 4 extensions to the brainstem, 1 extension to the contralateral thalamus, and 1 extension to the habenular commissure) |
| Cystic changes                              |                      |
| Yes                                         | 9 (27.3)            |
| No                                          | 24 (72.7)           |
| T1 and T2 signals                           |                      |
| Hypointense T1 and hyperintense T2          | 14 (42.4)           |
| Hypointense T1 and mixed T2                 | 2 (6.1)             |
| Mixed T1 and hyperintense T2                | 11 (33.3)           |
| Mixed T1 and T2                             | 6 (18.2)            |
| Enhancement                                 |                      |
| Yes                                         | 30 (90.9)           |
| No                                          | 3 (9.1)             |

| Table 3 Treatment details of 33 adult UTGs |
| Characteristics                             | No. (%) of patients |
| Approaches                                   |                     |
| Parieto-occipital transventricular approach  | 22 (66.7)           |
| Frontal transcortical approach               | 6 (18.2)            |
| Precentral interhemispheric transcalfosal interforniceal approach | 5 (15.2) |
| Extent of surgical resection                 |                      |
| Gross total tumor resection (≥90 %)          | 19 (57.6)           |
| Subtotal tumor resection (≥80 but <90 %)     | 9 (27.3)            |
| Partial tumor resection (<80 %)              | 5 (15.2)            |
| Location of residual tumor                   |                      |
| Posterior part of the third ventricle        | 3 (20)              |
| Lateral part of the thalamus adjacent to the internal capsule | 6 (40) |
| Medial and internal part of the thalamus     | 6 (40)              |
| Preoperative ventricular peritoneal shunt    |                      |
| Yes                                         | 7 (21.2)            |
| No                                          | 26 (78.8)           |
| Postoperative ventricular peritoneal shunt   |                      |
| Yes                                         | 4 (12.1)            |
| No                                          | 29 (87.9)           |
| Postoperative adjuvant therapy               |                      |
| Radiotherapy + chemotherapy                  | 10 (30.3)           |
| Radiotherapy                                 | 16 (48.5)           |
| Chemotherapy                                 | 2 (6.1)             |

*Percentage refers to the comparison reasons of the total residual tumor numbers of the patients (100 %)
cases; no obvious improvement was observed in the other 2 cases at the last follow-up. New dysphasia was observed in 3 cases, with transitory worsening and spontaneously regression within 3 months in all 3 cases. No new occurrence of hyperesthesia was observed in this series. No patient had seizures requiring additional antiepileptic medication pre- or postoperatively.

Recurrence and survival among patients with UTGs at follow-up
The follow-up period ranged from 1 week to 49 months; the median follow-up time was 17 months. At the last follow-up, 21 patients had experienced tumor progression. The median PFS was not available. The 1-year and 2-year PFS rates were 51.5 and 9.1 %, respectively. Twenty-one patients died of recurrent tumors, and the median OS was not available. The 1-year and 2-year OS rates were 72.7 and 24.2 %, respectively. Kaplan-Meier plots of PFS and OS are shown in Fig. 1.

Pathological features of UTGs
Pathological data are summarized in Table 1. Molecular pathology results were available in 15 of the 33 UTGs. Immunohistochemistry was positive for P53 in 69.2 % of the cases (9/13), Ki-67 in 90.9 % (10/11), GFAP in 90.9 % (10/11), MGMT in 60 % (6/10), VEGF in 60 % (6/10), TOPO-II in 80 % (8/10), P-170 in 50 % (5/10), MMP-9 in 90 % (9/10), GST-π in 80 % (8/10), PTEN in 100 % (9/9), EGFR in 66.7 % (6/9), Oligo-2 in 100 % (9/9), etc. (Table 4).

Clinical, radiological, and pathological parameters associated with PFS and OS
Parameters significantly associated with longer PFS and OS were determined using the log-rank test and Cox regression method (Table 5, Fig. 2, Additional files 1, 2, 3, 4, 5, 6, 7, and 8: Figures s1–s8). Univariate and multivariate analysis revealed several factors were correlated with a better PFS survival (Table 5). Also univariate and multivariate analysis revealed several factors were correlated with a better PFS survival (Table 5). Cox regression analysis revealed that age <42 years, female sex, symptom duration ≥ 2 months, cystic appearance, maximal tumor diameter < 3.9 cm, preoperative KPS ≥ 60, and gross total resection were associated with a better PFS prognosis, while left side (P = 0.259) and lower-pathological grade (P = 0.531) failed to show statistical significance of a better PFS survival. Cox regression analysis revealed that age < 42 years, female sex, left-sided tumor, symptom duration ≥ 2 months, cystic appearance, maximal tumor diameter < 3.9 cm, lower-pathological grade, preoperative KPS ≥ 60, gross total resection, and postoperative V-P shunt were also associated with a better OS prognosis (Additional file 9: Tables S1 and S2).

Illustrative cases
Case 1
A lesion affecting the left thalamus and midbrain was diagnosed radiologically in a 53-year-old male admitted to our hospital. He reported having headache for the past year and hypomnesia for the past 6 months. Neurological examination revealed no obvious abnormal findings. Radiological examination revealed a lesion located in the left thalamus and affecting the midbrain with hypointense T1 and hyperintense T2 signals as well as partial heterogeneous enhancement (Fig. 3). Thalamic glioma was diagnosed, and the patient underwent a subtotal resection of the tumor using a parieto-occipital transventricular approach. During surgery, the tumor appeared as a pinkish-gray soft mass with a poorly defined border and a cystic component of dark-yellow fluid in the posterior part of the mass. The postoperative pathology diagnosis was astrocytoma (WHO grade II). No immunohistochemical staining was performed. The patient suffered from a transient deterioration of the right limb motor function and language nonfluency after surgery. After 2 weeks, his limb movements returned to normal and his language fluency recovered. The patient was discharged 23 days after operation. Postoperative cranial radiotherapy was performed. However, the tumor progressed after 19 months. The patient refused to undergo another surgery, chemotherapy, or radiotherapy and died 25.5 months after the operation.
Case 33
A pathologic diagnosis of anaplastic astrocytoma with transformation to glioblastoma was confirmed in a 48-year-old male admitted to our hospital. He complained of a motor dysfunction of his right lower limb for the past 2 weeks. Neurological examination revealed weakness of his right lower limbs. The lesion showed mixed hypointense and isointense T1 and hyperintense T2 signals with clear enhancement (Fig. 4). The patient underwent a gross total resection using a parieto-occipital transventricular approach. During the operation, the tumor was found to be a gray-yellow soft mass with a poorly defined border. The postoperative pathology report confirmed the diagnosis of anaplastic astrocytoma with transformation to glioblastoma, which was immunopositive for MGMT, PTEN, GFAP, Oligo-2, MMP-9, P53 and immunonegative for EGFR, P-170, VEGF, TOPO-II, and GST-π. Limb weakness partially improved over a span of 2 weeks, and the patient was discharged 15 days after surgery. The postoperative follow-up revealed tumor recurrence at 1.5 months after surgery. The patient underwent postoperative concurrent chemoradiotherapy (radiotherapy + temozolomide) plus 10 cycles of temozolomide chemotherapy. The patient died 13 months after surgery.

Discussion
Several studies on thalamic glioma have been reported; however, the patient outcomes have been poor regardless of the type of treatment, and no comprehensive guidelines with regard to treatment are available [4–7, 11, 30]. Recent studies have demonstrated improved survival of pediatric patients with thalamic glioma after an aggressive tumor resection followed by postoperative adjuvant therapy [15, 28, 29]. However, the prognosis of thalamic glioma in adult patients after aggressive surgical treatment remains uncertain because adult thalamic glioma cases have always been assessed together with those of pediatric patients [3, 11, 18, 30–32], and no studies have been devoted solely to adult thalamic glioma. Therefore, the present retrospective study was undertaken to investigate the clinical features of unilateral thalamic gliomas in adults as well as to analyze the parameters that are likely to influence survival.

Basic clinical features correlated with prognosis
In the current series, several basic clinical features were found to correlate with a better prognosis, namely, age <42 years, symptom duration ≥2 months, and preoperative KPS ≥60. Some of the results in our series are in accordance with previously reported studies.

Age <42 years correlated with longer survival. This age of onset result was consistent with those of previous studies [1, 5, 33]. Moreover, previous studies also revealed better outcome in thalamic tumor patients who were younger than 40 years compared with older patients [5]. Similarly, Nishio et al. also demonstrated that the outcome of younger patients was better than that of older patients despite the same pathological diagnosis [4].

A symptom duration of ≥2 months was associated with longer survival. This, in the current series, a finding in agreement with a previous study [15]. Moreover, in our study, we found that a short duration of symptoms is often indicative of a high-grade glioma (WHO grades III and IV). In the subgroup of patients with symptom durations <2 months, the rate of high-grade glioma was 100 % (compared with a rate of 46.7 % in patients with symptom durations ≥2 months) ($P = 0.002$). This result is similar to the report of Cuccia [9].

A preoperative KPS ≥60 was correlated with longer survival and may be an independent factor for better OS. This result may reflect the fact that lower KPS may result in a decreased ability of patients to withstand neurological insults caused by the tumor, surgery, and/or adjuvant therapies [34–36]. The median KPS of the current study was

| Molecular pathologies | UTGs no. (%) | Molecular pathologies | UTGs no. (%) | Molecular pathologies | UTGs no. (%) |
|-----------------------|-------------|-----------------------|-------------|-----------------------|-------------|
| P53                   |             | TOPO-II               |             | GST-π                |             |
| +                     | 9(69.2)     | +                     | 8(80)       | +                     | 8(80)       |
| −                     | 4(30.7)     | −                     | 2(20)       | −                     | 2(20)       |
| GFAP                  |             | P-170                 |             | PTEN                 |             |
| +                     | 10(90.9)    | +                     | 5(50)       | +                     | 9(100)      |
| −                     | 1(9.1)      | −                     | 5(50)       | −                     | 0(0)        |
| MGMT                  |             | Oligo-2               |             | EGFR                 |             |
| +                     | 6(60)       | +                     | 9(100)      | +                     | 6(66.7)     |
| −                     | 4(40)       | −                     | 0(0)        | −                     | 3(33.3)     |
| VEGF                  |             | MMP-9                 |             |                      |             |
| +                     | 6(60)       | +                     | 9(90)       |                      |             |
| −                     | 4(40)       | −                     | 1(10)       |                      |             |

Table 4 Molecular pathology features of 33 adult UTGs
### Table 5 Parameters correlated with PFS and/or OS in 30 adult UTGs

| Characteristics | Median PFS (INR)* | Progression-free survival rates (%) | P value | Median OS (INR)* | Overall survival rates (%) | P value |
|-----------------|-------------------|-------------------------------------|---------|-------------------|-----------------------------|---------|
|                 | 6 months | 12 months | 18 months | 24 months | 6 months | 12 months | 18 months | 24 months |
| Age (years)     |          |          |          |          |          |          |          |          |
| <42             | N/A      | 87.5     | 62.5     | 25.0     | 6.3      | <0.001   | N/A      | 100.0    | 93.8     | 56.3     | 18.8     | <0.001   |
| ≥42             | N/A      | 64.3     | 50.0     | 28.6     | 14.3     |          | N/A      | 71.4     | 64.3     | 35.7     | 35.7     |          |
| Sex             |          |          |          |          |          |          |          |          |          |          |          |          |
| Male            | N/A      | 78.9     | 47.4     | 31.6     | 10.5     | 0.037    | N/A      | 94.7     | 84.2     | 57.9     | 36.8     | <0.001   |
| Female          | N/A      | 72.7     | 72.7     | 18.2     | 9.1      |          | N/A      | 72.7     | 72.7     | 27.3     | 9.1      |          |
| Lateral         |          |          |          |          |          |          |          |          |          |          |          |          |
| Left            | N/A      | 84.6     | 69.2     | 30.8     | 15.4     | <0.001   | N/A      | 92.3     | 92.3     | 46.2     | 38.5     | <0.001   |
| Right           | N/A      | 70.6     | 47.1     | 23.5     | 5.9      |          | N/A      | 82.4     | 70.6     | 47.1     | 17.6     |          |
| Preoperative kps|          |          |          |          |          |          |          |          |          |          |          |          |
| ≥60             | N/A      | 85.7     | 66.7     | 33.3     | 14.3     | <0.001   | N/A      | 95.2     | 90.5     | 52.3     | 23.8     | <0.001   |
| <60             | 9(3–20) | 55.6     | 33.3     | 11.1     | 0.0      |          | N/A      | 66.7     | 55.6     | 33.3     | 33.3     |          |
| Postoperative kps|         |          |          |          |          |          |          |          |          |          |          |          |
| ≥60             | N/A      | 84.0     | 72.0     | 36.0     | 16.0     | <0.001   | N/A      | 92.0     | 84.0     | 52.0     | 40.0     | <0.001   |
| <60             | N/A      | 40.0     | 20.0     | 0.0      | 0.0      |          | N/A      | 60.0     | 60.0     | 20.0     | 20.0     |          |
| Symptom duration (months) | |          |          |          |          |          |          |          |          |          |          |          |
| ≥2              | N/A      | 93.3     | 73.3     | 40.0     | 20.0     | <0.001   | N/A      | 93.3     | 93.3     | 66.7     | 46.7     | <0.001   |
| <2              | 11(2–24)| 60.0     | 40.0     | 13.3     | 0.0      |          | N/A      | 80.0     | 66.7     | 26.7     | 6.7      |          |
| Cystic changes  |          |          |          |          |          |          |          |          |          |          |          |          |
| Yes             | N/A      | 85.7     | 71.4     | 42.9     | 28.6     | <0.001   | N/A      | 100.0    | 100.0    | 85.7     | 57.1     | <0.001   |
| No              | N/A      | 73.9     | 52.2     | 21.7     | 4.3      |          | N/A      | 82.6     | 73.9     | 34.8     | 17.4     |          |
| Diameter (cm)   |          |          |          |          |          |          |          |          |          |          |          |          |
| <3.9            | N/A      | 91.7     | 66.7     | 41.7     | 16.7     | <0.001   | N/A      | 91.7     | 91.7     | 50.0     | 33.3     | <0.001   |
| ≥3.9            | N/A      | 66.7     | 50.0     | 16.7     | 5.5      |          | N/A      | 83.3     | 72.2     | 44.4     | 22.2     |          |
| Pathology       |          |          |          |          |          |          |          |          |          |          |          |          |
| Low grade       | N/A      | 100.0    | 100.0    | 50.0     | 25.0     | <0.001   | N/A      | 100.0    | 100.0    | 75.0     | 50.0     | <0.001   |
| High grade      | N/A      | 68.2     | 40.9     | 18.2     | 4.5      |          | N/A      | 81.8     | 72.7     | 36.4     | 18.2     |          |
| Postoperative v-p shunt | |          |          |          |          |          |          |          |          |          |          |          |
| Yes             | 14.5 (12–24)| 100.0    | 75.0     | 25.0     | 0.0      | –        | N/A      | 100.0    | 100.0    | 50.0     | 25.0     | <0.001   |
| No              | N/A      | 73.1     | 53.8     | 26.9     | 11.5     |          | N/A      | 84.6     | 76.9     | 46.2     | 26.9     |          |
| Resection       |          |          |          |          |          |          |          |          |          |          |          |          |
| Gtr             | N/A      | 82.4     | 64.7     | 35.3     | 17.6     | <0.001   | N/A      | 88.2     | 76.5     | 52.9     | 35.3     | <0.001   |
| Str/pr          | 12(2–20)| 69.2     | 46.2     | 15.4     | 0.0      |          | N/A      | 84.6     | 84.6     | 38.5     | 15.4     |          |

N/A not available
*Median PFS and median OS was calculated based on the final status of follow-up
*bMeans no correlation in univariate analysis
Fig. 2 Patients with low-grade pathology have longer PFS (a) and OS (b) than patients with high-grade. Gross total tumor resection is significantly associated with longer PFS (c) and OS (d).

Fig. 3 Case 1. Cranial MRI examination revealed unilateral thalamus glioma located in the left thalamus and midbrain with hypointense T1 (a) and hyperintense T2 (b) signals, which were heterogeneously enhanced after injecting contrast agent (c–e). Postoperative MRI confirmed subtotal resection (f–j). Pathological examination revealed a diagnosis of astrocytoma (WHO Grade II). Original magnification ×100.
a lower KPS score was observed in 9 cases (30%), which is substantially lower rate than previously reported [6, 37]. The result of this study indicates that performance of thalamic patients was substantially worse on admission than for patients with glioma in other parts of the brain, which points to a higher surgical risk when performing a tumor resection in these patients. Of note, the 3 (pre-operative KPS categories 40, 50, and 60, respectively) developed within 2 weeks after surgery in this group of patients.

**Tumor biological features correlated with prognosis**

Tumors with cystic appearance were correlated with longer survival. The rate of cystic appearance in our study was 24.2%, which is similar to the rate of 11.5–53% in previous studies [13, 15, 38]. All cystic components as well as the walls of the cysts were completely excised during surgery. This approach is in accordance with Moshe’s study because cystic thalamic tumors also contain tumor cells in the cyst wall [38]. The pathology of tumors with cystic appearance in our study included astrocytoma in 4 cases, oligodendroastrocytoma in 1 case, anaplastic astrocytoma in 1 case, anaplastic oligodendroastrocytoma in 1 case, and glioblastoma in 1 case. No thalamus pilocytic astrocyomas were present in our study; this result is notably different from the thalamic tumors observed in children [15, 39].

A maximal tumor diameter of <3.9 cm correlated with longer survival. Few studies have indicated a correlation between tumor diameter and survival [11, 16]. Although, a previous study on pediatric thalamic glioma, Kramm failed to show a significant correlation between tumor diameter and survival [16], larger tumors may present more challenges to surgeons [38].

Low-grade pathology was correlated with longer survival and was also an independent factor for better OS. Tumor pathology has been generally accepted as key factor influencing survival [8, 28, 33]. Modern neuroimaging methods have contributed to a better understanding of the patterns of tumor growth. Thalamic gliomas are thought to grow along three primary pathways: along the white matter, underneath the ventricular ependyma, and through the cerebrospinal fluid pathways [8, 40]. Subsequently, surrounding tissues, such as the internal capsule, the basal ganglia, the mesencephalic tegmentum, and the hypothalamic structures (and their corresponding functions), may be affected [22, 41]. From this point of view, patients with glioma of higher pathology grade may be more strongly affected by the malignancy features and face a higher risk during surgery and other comprehensive treatments.

**Clinical treatment correlated with prognosis**

CSF has long been a problem in thalamic glioma patients. Thalamic gliomas are apt to cause obstruction of the third or lateral ventricles. V-P shunt is one of the most accepted procedures for maintaining CSF circulation. Baroncini discussed CSF obstruction in pediatric thalamic glioma patients [28]; however, the correlation between V-P shunt and patient survival has never been examined. In the present study, we analyzed the correlation between survival and V-P shunt due to perioperative acute hydrocephalus. We found that postoperative V-P shunt correlated with longer OS. The infiltrative nature and the growth pattern of thalamic glioma likely contribute to the worsening of patients’ clinical status [40]. Based on these results, we also hypothesize that the occlusion of CSF circulation may be another main contributor to the poor prognosis because ventriculomagely and/or hydrocephalus were present in nearly all reported series.
Gross total tumor resection correlated with longer survival. Thalamic gliomas have long been a challenge and are considered difficult to excise. Most of these tumors received only partial resection, biopsy, or only radiotherapy for palliative care in earlier studies. However, with the advancement of microsurgical techniques, recent studies have reported improved survival following aggressive tumor resection in pediatric thalamic glioma patients [15, 28, 29], which indicates that current cases of thalamic glioma can be resected with acceptable complications nowadays. The present study, focused exclusively on adult UTG patients, found a statistically significant correlation between gross total tumor resection and survival. Therefore, more aggressive cytoreductive treatments should also be considered for these tumors.

Study limitations
This retrospective study was based on a small series of cases. Consequently, our conclusions were based on the statistical analysis of a small number of patients and should be interpreted with caution.

Conclusions
Unilateral thalamic glioma in adults represents a distinct clinical subtype of thalamic gliomas. Tumors with specific features, such as cystic appearances in radiology, may indicate better prognosis. Moreover, using perioperative ultrasound techniques and improved surgical techniques, maximal safe resection was often feasible and provided prognostic benefits with UTGs. However, the more fundamental biological features and the recommendation of maximal safe resection for UTGs whenever possible to promote prolonged survival still need to be further investigated in larger series.

Additional files

Additional file 1: Figure S1. Age <42 years is significantly associated with longer PFS (A) and OS than age ≥42 years (B). (TIF 55 kb)

Additional file 2: Figure S2. Male patients have longer PFS (A) and OS (B) than female patients. (TIF 56 kb)

Additional file 3: Figure S3. Patients with left-sided tumor have a longer PFS (A) and OS (B) than patients with right-sided tumor. (TIF 57 kb)

Additional file 4: Figure S4. Patients with preoperative KPS ≥60 have longer PFS (A) and OS (B). (TIF 57 kb)

Additional file 5: Figure S5. Patients with symptom duration longer than 2 months have longer PFS (A) and OS (B). (TIF 55 kb)

Additional file 6: Figure S6. Patients with cystic changes of tumor is significantly associated with longer PFS (A) and OS than patients without this changes (B). (TIF 57 kb)

Additional file 7: Figure S7. Maximal tumor diameter <3.9 cm is associated with longer PFS (A) and OS (B). (TIF 56 kb)

Additional file 8: Figure S8. Postoperative V-P shunt is significantly associated with longer OS. (TIF 40 kb)

Additional file 9: Tables s1 and s2. Cox-regression analysis for PFS and OS, respectively. (DOCX 41 kb)

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
PZ carried out the clinical data collection, statistical analysis, and manuscript drafting and modification. XW, XR, GS, and RW helped in the clinical data collection and statistical analysis. NJ, JX, and JH participate in the design of the study and the modification of the manuscript. LZ and ZG both conceived of the study and participated in the coordination. All authors read and approved the final manuscript.

Acknowledgements
This work was supported by the National Key Technology Research and Development Program of the Ministry of Science and Technology of China (2013BA09B03) and Beijing Institute for Brain Disorders (BIBD-PXM2013_014 226_07_000084).

Author details
1 Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China. 2 China National Clinical Research Center for Neurological Diseases (NCRC-ND), Beijing 100050, China. 3 Beijing Key Laboratory of Brain Tumor, Beijing 100050, China. 4 Department of Neurosurgery, Beijing Puren Hospital, Beijing 100069, China.

Received: 3 December 2015 Accepted: 29 February 2016
Published online: 10 March 2016

References
1. Cheek WR, Taveras JM. Thalamic tumors*. J Neurosurg. 1966;24:505–13.
2. Mckissock W, Paine KW. Primary tumours of the thalamus. Brain. 1958;81:41–63.
3. Tovi D, Schiavo G, Lijefvist B. Primary tumors of the region of the thalamus. J Neurosurg. 1961;17:30–40.
4. Nishio S, Moritaka T, Suzuki S, Takeshiba I, Fukui M. Thalamic gliomas: a clinicopathologic analysis of 20 cases with reference to patient age. Acta Neurochir. 1997;139:336–42.
5. Franzini A, Leocata F, Cajola L, Servello D, Allegranza A, Broggi G. Low-grade glial tumors in basal ganglia and thalamus: natural history and biological reappraisal. Neuropsychology. 1994;55:817–21.
6. Krouwer HG, Prados MD. Infiltrative astrocytomas of the thalamus. J Neurosurg. 1995;82:548–57.
7. Pathy S, Jayalakshmi S, Chander S, Singh R, Julka P, Rath G. Prognostic factors influencing the outcome of thalamic glioma. Neurol India. 2002;50:37.
8. Bernstein M, Hoffman HI, Halliday WC, Hendrick EB, Humphreys RP. Thalamic gliomas in children: long-term follow-up and treatment guidelines. J Neurosurg. 1984;61:649–56.
9. Guccia V, Monges J. Thalamic tumors in children. Childs Nerv Syst. 1997;13:514–21.
10. Reedon DA, Gajjar A, Sanford RA, Heideman RL, Walter AW, Thompson SJ, Merchant TE, Li H, Jenkins JJ, Langston J. Bithalamic involvement predicts poor outcome among children with thalamic glial tumors. Pediatr Neurosurg. 1998;29:29–35.
11. Steiger H-J, Götz C, Schmid-Elasaesser R, Stummer W. Thalamic astrocytomas: surgical anatomy and results of a pilot series using maximum microsurgical removal. Acta Neurochir. 2000;142:1327–37.
12. Albright AL. Feasibility and advisability of resections of thalamic tumors in pediatric patients. J Neurosurg Pediatr. 2004;100:468–72.
13. Fernandez C, de Paula AM, Colin C, Quilichini B, Bouvier-Labit C, Girard N, Scavarda D, Lena G, Figarella-Branger D. Thalamic gliomas in children: an extensive clinical, neuroradiological and pathological study of 14 cases. Childs Nerv Syst. 2006;22:1603–10.
14. Bronisera A, Chintagumpala M, Fouladi M, Krasin MJ, Kocak M, Bowers DC, Iacono LC, Merchant TE, Stewart CF, Houghton PJ, Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurosurg. 2006;103:313–9.
15. Pujet S, Crémmins DW, Garnett MR, Grill J, Okieva R, Doddlaert N, Way A, Lefouch-Tubiana A, Roujeau T, Di Rocco F. Thalamic tumors in children: a reappraisal. J Neurosurg Pediatr. 2007;10:634–62.
16. Kramm CM, Butenhoffer S, Rausch U, Warmuth-Metz M, Kortmann RD, Pietsch T, Grekow A, Jurch N, Janssen G. Breastfeeding F. Thalamic high-grade gliomas in children: a distinct clinical subset? Neuro Oncol. 2011;13:680–9.
17. Greenwood Jr J. Radical surgery of tumors of the thalamus, hypothalamus, and third ventricle area. Surg Neurol. 1973;1:29.
18. McGirr SJ, Kelly PJ, Scheithauer BW. Stereotactic resection of juvenile pilocytic astrocytomas of the thalamus and basal ganglia. Neurosurgery. 1987;20:447–52.
19. Scott E, Middle J. Pediatric diencephalic gliomas—a review of 18 cases. Pediatr Neurosurg. 1987;13:225–32.
20. Lyons M, Kelly P. Computer-assisted stereotactic biopsy and volumetric resection of thalamic pilocytic astrocytomas. Stereotact Funct Neurosurg. 1992;59:100–4.
21. Matsumoto K, Higash H, Tomita S, Furuta T, Ohmoto T. Resection of deep-seated gliomas using neuromapping for stereotactic placement of guidance catheters. Neurol Med Chir. 1995;35:148–55.
22. Martínez-Lage JF, Pérez-Espejo MA, Esteban JA, Poza M. Thalamic tumors: clinical presentation. Childs Nerv Syst. 2002;18:405–11.
23. Ruel J, Broussole E, Gonnaud P, Jouvet A, Rousselle C, Chazot G. Bilateral thalamic glioma. A clinicopathological study of 2 cases. Rev Neurol. 1991;148:742–5.
24. Partlow GD, del Carpio-O’Donovan R, Melanson D, Peters TM. Bilateral thalamic glioma: review of eight cases with personality change and mental deterioration. Am J Neuroradiol. 1992;13:1225–30.
25. Yoshida M, Fushiki S, Takeuchi Y, Takashni M, Imamura T, Shikata T, Morimoto A, Konishi K, Miyazaki A, Sawada T. Diffuse bilateral thalamic astrocytomas as examined serially by MRI. Childs Nerv Syst. 1998;14:384–8.
26. Itatani H, Yokoyama S, Nakayama M, Nagata S, Kuratsu J. Bilateral thalamic glioma: case report. Neuroradiology. 2000;42:732–4.
27. Uchino M, Kitajima S, Miyazaki C, Shibata I, Miura M. Bilateral thalamic glioma. Case report. Neurol Med Chir. 2002;42:443–6.
28. Barocini M, Vinchon M, Mineo J-F, Pichon F, Francke J-P, Dhellemmes P. Surgical resection of thalamic tumors in children: approaches and clinical results. Childs Nerv Syst. 2007;23:753–60.
29. Wisoff JH, Boyett JM, Berger MS, Brant C, Li H, Yates AJ, McGuire-Cullen P, Turski PA, Sutton LN, Allen JC. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children’s Cancer Group trial no. CCG-945. J Neurosurg. 1998;89:52–9.
30. Kelly PJ. Stereotactic biopsy and resection of thalamic astrocytomas. Neurosurgery. 1989;25:185–95.
31. Arseni C. Tumors of the basal ganglia: their surgical treatment. AMA Arch Neurol Psychiat. 1958;80:18–24.
32. Prakash B. Surgical approach to large thalamic gliomas. Acta Neurochir. 1985;74:100–4.
33. Kurian K, Zhang Y, Haynes H, Macaskill N, Bradley M. Diagnostic challenges of primary thalamic gliomas—identification of a minimally enhancing neuroradiological subtype with aggressive neuropathology and poor clinical outcome. Clin Neuroradiol. 2013;24:231–8.
34. Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol. 2004;6:227–35.
35. Laws ER, Parney IF, Lillehei KO, Asher A. Stereotactic resection of thalamic pilocytic astrocytomas. Neurosurgery. 2004;55:475–8.
36. Krauss JK, Braus DF, Mohadjer M, Nobbe F, Munding F. Evaluation of the effect of treatment on movement disorders in astrocytomas of the basal ganglia and the thalamus. J Neurol Neurosurg Psychiatry. 1993;56:1113–8.
37. Laws ER, Parney IF, Lillehei KO, Asher A, Lillehei KO, Bernstein M, Brem H, Sloan A. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003;99:467–73.
38. Kten D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G. Long-term survival with glioblastoma multiforme. Brain. 2007;130:666–67.
39. Krauss JK, Braus DF, Mohadjer M, Nobbe F, Munding F. Evaluation of the effect of treatment on movement disorders in astrocytomas of the basal ganglia and the thalamus. J Neurol Neurosurg Psychiatry. 1993;56:1113–8.
40. Moshel YA, Link MJ, Kelly PJ. Stereotactic volumetric resection of thalamic pilocytic astrocytomas. Neurosurgery. 2007;61:66–75.
41. Sainte-Rose C, Crimmins DW, Grill J. Thalamic gliomas. In Oncology of CNS Tumors. Springer: 2010:405–417.
42. Amin MR, Kamitani H, Watanabe T, Ishibashi M, Ogawa T, Funakoshi T, Miya H, Ohama E. A topographic analysis of the proliferating tumor cells in an autopsied brain with infiltrative thalamic glioma. Brain Tumor Pathol. 2002;19:5–10.
43. Souweidane MM, Hoffman HJ. Current treatment of thalamic gliomas in children. J Neurooncol. 1996;28:157–66.